Takeda Pharmaceuticals (TAK.US) TAK-861 achieved positive results in two key phase III studies for treating type 1 narcolepsy.

According to the Wisdom Financial APP, on July 14, Takeda Pharmaceutical (TAK.US) announced that two Phase III randomized, double-blind, placebo-controlled studies of Oveporexton (TAK-861) for type 1 narcolepsy with cataplexy (NT1) met all primary and secondary endpoints. Oveporexton (TAK-861) is a potential novel oral selective orexin 2 receptor (OX2R) agonist being studied for the treatment of type 1 narcolepsy with cataplexy (NT1).